No Data
No Data
Express News | Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target
Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Announces Safety Review Results Of SON-1010 In Combination With Trabectedin For Advanced Soft Tissue Sarcomas, Showing No Unexpected Toxicities And Clinical Benefit In 83% Of Patients, Paving The Way For Full Enrollment In Phase...
Express News | Sonnet Biotherapeutics Holdings : Safety Review Committee Found No Unexpected Toxicities in Early Dosing of Son-1010 in First 7 Patients at Mtd
Sonnet BioTherapeutics Announces Notice of Allowance for Second Patent on Variant Interleukin-18 Binding Protein for Enhanced Cancer Therapeutics
Sonnet BioTherapeutics Receives Notice Of Allowance For U.S. Patent Covering Composition Of Matter Of Specific Amino Acid Substitutions Of Its IL-18 Binding Protein Resistant Variant Protein